TransCode Therapeutics Inc (RNAZ)

[subslover]

TransCode Therapeutics Reports Positive Preclinical Results with its Lead Candidate, TTX-MC138, in Pancreatic Adenocarcinoma
10/26/2022 | 07:01am EDT
share with twitter
share with LinkedIn
share with facebook
BOSTON, Oct. 26, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported Positive Preclinical Results with its Lead Candidate, TTX-MC138, in Pancreatic Adenocarcinoma.

TransCode Therapeutics evaluated the bioactivity of its lead therapeutic candidate, TTX-MC138, applied as monotherapy, in a murine model of pancreatic adenocarcinoma. In the study, mice bearing human pancreatic tumors implanted in their pancreas were treated once weekly for 10 weeks with TTX-MC138. The drug demonstrated a pharmacodynamic response by successfully inhibiting its target, microRNA-10b (miR-10b), as measured by qRT-PCR, a commonly used assay for measuring gene expression. Serum miR-10b, a possible surrogate biomarker of therapeutic efficacy, was down-regulated by TTX-MC138 in this study. Forty percent of animals treated with TTX-MC138 had complete responses, defined as complete regression of disease and long-term survival without recurrence. Additional studies to better define the optimal dose and therapeutic window in pancreatic cancer are ongoing.

These new findings potentially expand the therapeutic relevance of TTX-MC138 to also include pancreatic adenocarcinoma. “TTX-MC138 has already been shown to induce durable regression of metastatic breast cancer in murine models, so with an outlook toward evaluating other solid tumor types that express miR-10b, our next step was to test the applicability of our therapeutic strategy in a pancreatic cancer model,” commented Zdravka Medarova, PhD, co-founder and CTO of TransCode. “As with prior studies, we believe the data from this pancreatic cancer study further support advancement of TTX-MC138 into the clinic. These preclinical data increase our confidence that TTX-MC138 has the potential to become a novel first-in-class therapeutic approach against advanced solid tumors that could ultimately improve clinical outcomes in human patients.”






“Demonstrating successful treatment using our first-in-class RNA-targeted therapeutic candidate in a variety of solid tumor models is an important step in the preclinical development process and, we believe, further de-risks our approach,” added Michael Dudley, co-founder, president and CEO of TransCode. “As we have previously indicated, we are on track to submit an exploratory Investigational New Drug Application (eIND) this year for our planned Phase 0 first-in-human (FIH) clinical trial with TTX-MC138 in cancer patients with advanced solid tumors.”

TTX-MC138 targets microRNA-10b, believed to drive metastatic disease. TTX-MC138 has been validated preclinically in multiple indications and has previously been shown to induce durable regression of metastatic disease in murine models of disseminated breast cancer.

About TransCode Therapeutics

TransCode is an RNA oncology company created on the belief that cancer can be effectively treated using RNA therapeutics. The Company has created a platform of drug candidates designed to target a variety of tumor types with the objective of significantly improving patient outcomes. The Company’s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which is believed to cause approximately 90% of all cancer deaths totaling over nine million per year worldwide. The Company believes that TTX-MC138 has the potential to produce regression with